Results 321 to 330 of about 331,561 (389)
Some of the next articles are maybe not open access.
Intravenous Immunoglobulin Therapy
Comprehensive Dermatologic Drug Therapy, 2021Mathias Sulk +2 more
openaire +2 more sources
Hematologic toxicities associated with intravenous immunoglobulin therapy
International Immunopharmacology, 2011Intravenous immunoglobulin (IVIG) is an immunomodulating agent that induces beneficial therapeutic responses in children and adults. IVIG is not only used for prophylaxis and therapy of infections in patients with primary and secondary immunodeficiencies associated with defective antibody production, but also used for treatment of patients with ...
Allison, Baxley, Mojtaba, Akhtari
openaire +3 more sources
Intravenous immunoglobulin therapy: how does IgG modulate the immune system?
Nature Reviews Immunology, 2013I. Schwab, F. Nimmerjahn
semanticscholar +3 more sources
Human intravenous immunoglobulin therapy
Seminars in Veterinary Medicine and Surgery: Small Animal, 1997Human intravenous immunoglobulin (hIVIG) is a preparation of normal polyspecific IgG obtained from the plasma of healthy blood donors. Although purified immunoglobulins were initially developed for treatment of primary immunodeficiency syndromes, they have since been documented to be effective in the treatment of some immune-mediated diseases such as ...
J. Catharine +2 more
openaire +2 more sources
American Journal of Therapeutics, 2019
BACKGROUND Intravenous immunoglobulin (IVIG) has recognized efficacy in autoimmune peripheral nerve disorders, but there has been limited study of the use of IVIG in autoimmune dysautonomias.
J. Schofield, K. Chémali
semanticscholar +1 more source
BACKGROUND Intravenous immunoglobulin (IVIG) has recognized efficacy in autoimmune peripheral nerve disorders, but there has been limited study of the use of IVIG in autoimmune dysautonomias.
J. Schofield, K. Chémali
semanticscholar +1 more source
Pediatric Blood & Cancer, 2019
This study aimed to investigate the relationship between CD4+ regulatory T cells (Tregs) and innate lymphoid cells (ILCs) in children with primary immune thrombocytopenia (ITP) undergoing high‐dose intravenous immunoglobulin (IVIG) therapy.
Shih‐Chung Wang +6 more
semanticscholar +1 more source
This study aimed to investigate the relationship between CD4+ regulatory T cells (Tregs) and innate lymphoid cells (ILCs) in children with primary immune thrombocytopenia (ITP) undergoing high‐dose intravenous immunoglobulin (IVIG) therapy.
Shih‐Chung Wang +6 more
semanticscholar +1 more source
Historic aspects of intravenous immunoglobulin therapy
Cancer, 1991The earliest preparations of immunoglobulins (Ig) decreased the susceptibility of agammaglobulinemic patients to infections caused by pneumococci, Haemophilus influenzae, meningococci, streptococci, and Pseudomonas aeruginosa. Intramuscular administration of such preparations was painful and traumatic, especially for children.
R A, Good, E, Lorenz
openaire +2 more sources
Safety of intravenous immunoglobulin (IVIG) therapy
Autoimmunity Reviews, 2007Intravenous immunoglobulin (IVIg) is administered both for the treatment of immunodeficiencies and for an expanding list of autoimmune diseases. Most adverse effects are mild and transient including headaches, flushing, fever, chills, fatigue, nausea, diarrhea, blood pressure changes and tachycardia.
Uriel, Katz +3 more
openaire +2 more sources
Intravenous immunoglobulin therapy of lupus pneumonitis
The Indian Journal of Pediatrics, 2007Acute lupus pneumonitis in an 11-year-old girl with lupus nephritis is reported. Chest radiograph and arterial blood gas parameters were suggestive of Acute Respiratory Distress Syndrome (ARDS). Definitive pulmonary infection was excluded by investigations and poor clinical response to antibiotics.
G, Chetan +3 more
openaire +2 more sources
Adverse Effects of Intravenous Immunoglobulin Therapy
Drug Safety, 1999A growing body of literature documents that intravenous immunoglobulin prophylaxis and therapy is becoming applied to a steadily growing list of new indications. Some of these new indications have led to the use of intravenous immunoglobulin therapy in doctors offices, far from the hospital environment.
U E, Nydegger, M, Sturzenegger
openaire +2 more sources